^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/24/2022
    Excerpt:
    REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with...Previously treated follicular lymphoma (FL), in combination with a rituximab product...
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    06/14/2007
    Excerpt:
    Revlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    In relapsed FL, lenalidomide plus rituximab may be considered for patients with short remissions after ChT [II, B]….In later relapses, a non-ChT approach is recommended [III, C]: lenalidomide plus rituximab [II, B]…
    DOI:
    10.1016/j.annonc.2020.11.008
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Follicular Lymphoma: First-line therapy…Preferred regimens…Lenalidomide + rituximab
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    HEMO 2020
    Title:

    INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL).

    Published date:
    11/26/2020
    Excerpt:
    …in pts with R/R FL gr1-3a, MZL…lenalidomide 20 mg/d, d1-21/28 + rituximab 375 mg/m2/wk c1 and then q8wk c3+ (R2) are given...ORR was 69% with 40% CR/CRu. Median DOR was 39.0 mo, and median PFS was 40.1 mo…
    DOI:
    10.1016/j.htct.2020.10.372
    Trial ID:
    MAGNIFY